XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia

XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia 34 Bibliografía 1. CammAJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-47. 2. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology. Atrial Fibrillation in Cancer. J Am Coll Cardiol 2014; 63(10):945-53. 3. Hu YF, Liu CJ, Chang PM, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 2013;165:355-7. 4. Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk for atrial fibrillation after lung cancer surgery: analysis of the Society of Throracic Surgeons general thoracic surgery database. Ann Thorac Surg 2010; 90: 368-74. 5. Imperatori A , Mariscalco G, Riganti G, Rotolo N, Conti V, Domin- ioni L. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Car- diothorac Surg 2012;7:4. 6. Roselli EE, Murthy SC, Rice TW, et al. Atrial fibrillation com- plicating lung cancer resection. J Thorac Cardiovasc Surg 2005;130:438-44. 7. Siu CW, Tung HM, Chu KW, Jim MH, Lau CP,Tse HF. Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer. Pacing Clin Electrophysiol 2005;28(1):S120-3. 8. Bhave PD, Goldman LE, Vittinghoff E, Maselli J, Auerbach A. Incidence, predictors, and outcomes associated with postopera- tive atrial fibrillation after major noncardiac surgery. Am Heart J 2012;164:918-24. 9. Mann DL, Krone RJ. Cardiac disease in cancer patients: an over- view. Prog Cardiovasc Dis 2010;53:80-7. 10. Guzzetti S, Costantino G, Fundaro C. Systemic inflammation, atrial fibrillation, and cancer. Circulation 2002;106:e40. 11. Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE. Drug-induced atrial fibrillation. Drugs 2012;72:1617-30. 12. SuterTM, Ewer MS. Cancer drugs and the heart:importance and mangement. Eur Heart J 2013;34:1102-11. 13. Lainscak M, Dagres N, Filippatos GS, Anker SD, Kremastinos DT. Atrial fibrillation in chronic non-cardiac disease: where do we stand? Int J Cardiol 2008;128:311-5. 14. Mery B, Guichard JB, Guy JB, Vallard A, Barthelemy JC, Da Cos- ta A, Magné N, Bertoletti L. Atrial fibrillation in cancer patients: Hindsight,insight and foresight. Int J Cardiol 2017;240:196-202. 15. Fitzpatrick T, Carrier M, Le Gal G. Cancer, atrial fibrillation , and stroke. Thromb Res 2017;155:101-5. 16. Katritsis DG, Gersh BJ, Camm AJ. Anticoagulation in Atril Fibril- lation,current concepts. Arrhytmia & Electrophysiology Review 2015;4(2):100-7. 17. Farge D, Debourdeau P, Beckers M et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013;11:56-70. 18. Ambrus DB, Reisman JI, Rose AJ. The impact of new-onset can- cer among veterans who are receiving warfarin for atrial fibrilla- tion and venous thromboembolism. Thromb Res 2016;144:21-6; PMID:27270218. 19. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora Silvio, Noonan DM. Cardiotoxicity of anticancer drugs: The need for car- dio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25. 20. Short NJ, Connors JM. New oral anticoagulants and the cancer patients. The Oncologist 2014;19:82-93. 21. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran ver- sus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. 22. Patel MR, Mahaffey KW, Garg L, et al. Rivaroxaban versus warfari- na in non valvular atrial fibrillation. N Engl J Med 2011;365:883-91. 23. Granger CB, Alexander JH, Mc Murray JJ, et al. Apixaban ver- sus warfarina in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. 24. Giugliano RP, Ruff CT, Braunwald E, for the ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarina in patients with atrial fibrillation. NEJM 2013;34:1498-505. 25. Melloni C, DunningA, Granger CB, et al. Efficacy and safety of apix- aban versus warfarin in patients with atrial fibrillation and active can- cer: insights from theARISTOTLE trial, NewTrends inAntithrombot- ic Therapy forAtrial Fibrillation,August 2016 (Symposium conducted at the European Society of Cardiology Congress 365, Rome, Italy). 26. Laube ES, Yu A, Gupta D et al. Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer. AM J Cardiol 2017. 27. 2016 ESC Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines. European Heart Journal 2016;37:2768-801.

RkJQdWJsaXNoZXIy OTU4MzI=